Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378216097> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4378216097 endingPage "279" @default.
- W4378216097 startingPage "274" @default.
- W4378216097 abstract "Abstract: 
 Objective: Soft tissue sarcomas are heterogeneous group of malignancies consisting of more than 50 subtypes. Although it is rare, it is usually resistant to chemotherapy and has a poor prognosis. In this study, we planned to investigate the efficacy, tolerability and side-effect profile of pazopanib in metastatic soft tissue sarcomas.
 Method-Material: Our study was a single-center retrospective study and included metastatic patients over the age of 18 who were treated with pazopanib. Data of 37 patients were obtained in retrospective medical records. In patients using pazopanib; Tumor location, histological subtype, tumor grade, disease stage, the line at which pazopanib was used, efficacy, tolerability, and side-effect profile of pazopanib were examined.
 Findings: The mean age of the patients at diagnosis was 49. Pleomorphic sarcoma was the most common subtype. The progression-free survival (PFS) of patients after first-line therapy was 18 weeks. The median overall survival (OS) of the patients was 20 months. The median PFS with pazopanip was 18 weeks.
 Conclusion: In the study we conducted research in terms of effectiveness and side effects; the use of pazopanib in soft tissue sarcoma was found to be effective in terms of both PFS and OS. Side effects were tolerable and treatable. In our study, a PFS of 32 weeks was obtained in patients with hypothyroidism and at 16 weeks in patients who did not. In this respect, development of hypothyroidism may be a predictive parameter for response." @default.
- W4378216097 created "2023-05-26" @default.
- W4378216097 creator A5003375619 @default.
- W4378216097 creator A5017203819 @default.
- W4378216097 creator A5022118788 @default.
- W4378216097 creator A5039546859 @default.
- W4378216097 creator A5082156791 @default.
- W4378216097 date "2023-06-30" @default.
- W4378216097 modified "2023-10-18" @default.
- W4378216097 title "REAL-LIFE DATA OF PAZOPANIB USAGE IN SOFT TISSUE SARCOMA" @default.
- W4378216097 cites W1556311442 @default.
- W4378216097 cites W1964977762 @default.
- W4378216097 cites W1984960550 @default.
- W4378216097 cites W2065902287 @default.
- W4378216097 cites W2075485315 @default.
- W4378216097 cites W2082065626 @default.
- W4378216097 cites W2088074688 @default.
- W4378216097 cites W2098696397 @default.
- W4378216097 cites W2099022883 @default.
- W4378216097 cites W2101776780 @default.
- W4378216097 cites W2153775283 @default.
- W4378216097 cites W2154117685 @default.
- W4378216097 cites W2163258576 @default.
- W4378216097 cites W2275599683 @default.
- W4378216097 cites W2837084393 @default.
- W4378216097 cites W3006093091 @default.
- W4378216097 cites W4206841660 @default.
- W4378216097 doi "https://doi.org/10.18663/tjcl.1236710" @default.
- W4378216097 hasPublicationYear "2023" @default.
- W4378216097 type Work @default.
- W4378216097 citedByCount "0" @default.
- W4378216097 crossrefType "journal-article" @default.
- W4378216097 hasAuthorship W4378216097A5003375619 @default.
- W4378216097 hasAuthorship W4378216097A5017203819 @default.
- W4378216097 hasAuthorship W4378216097A5022118788 @default.
- W4378216097 hasAuthorship W4378216097A5039546859 @default.
- W4378216097 hasAuthorship W4378216097A5082156791 @default.
- W4378216097 hasBestOaLocation W43782160971 @default.
- W4378216097 hasConcept C121608353 @default.
- W4378216097 hasConcept C126322002 @default.
- W4378216097 hasConcept C141071460 @default.
- W4378216097 hasConcept C142724271 @default.
- W4378216097 hasConcept C143998085 @default.
- W4378216097 hasConcept C167135981 @default.
- W4378216097 hasConcept C195910791 @default.
- W4378216097 hasConcept C197934379 @default.
- W4378216097 hasConcept C2776694085 @default.
- W4378216097 hasConcept C2778256501 @default.
- W4378216097 hasConcept C2778375690 @default.
- W4378216097 hasConcept C2778439243 @default.
- W4378216097 hasConcept C2778629024 @default.
- W4378216097 hasConcept C2779490328 @default.
- W4378216097 hasConcept C71924100 @default.
- W4378216097 hasConceptScore W4378216097C121608353 @default.
- W4378216097 hasConceptScore W4378216097C126322002 @default.
- W4378216097 hasConceptScore W4378216097C141071460 @default.
- W4378216097 hasConceptScore W4378216097C142724271 @default.
- W4378216097 hasConceptScore W4378216097C143998085 @default.
- W4378216097 hasConceptScore W4378216097C167135981 @default.
- W4378216097 hasConceptScore W4378216097C195910791 @default.
- W4378216097 hasConceptScore W4378216097C197934379 @default.
- W4378216097 hasConceptScore W4378216097C2776694085 @default.
- W4378216097 hasConceptScore W4378216097C2778256501 @default.
- W4378216097 hasConceptScore W4378216097C2778375690 @default.
- W4378216097 hasConceptScore W4378216097C2778439243 @default.
- W4378216097 hasConceptScore W4378216097C2778629024 @default.
- W4378216097 hasConceptScore W4378216097C2779490328 @default.
- W4378216097 hasConceptScore W4378216097C71924100 @default.
- W4378216097 hasIssue "2" @default.
- W4378216097 hasLocation W43782160971 @default.
- W4378216097 hasLocation W43782160972 @default.
- W4378216097 hasOpenAccess W4378216097 @default.
- W4378216097 hasPrimaryLocation W43782160971 @default.
- W4378216097 hasRelatedWork W1805852575 @default.
- W4378216097 hasRelatedWork W2026017440 @default.
- W4378216097 hasRelatedWork W2318766411 @default.
- W4378216097 hasRelatedWork W2566089246 @default.
- W4378216097 hasRelatedWork W2901280698 @default.
- W4378216097 hasRelatedWork W2921652393 @default.
- W4378216097 hasRelatedWork W2940672269 @default.
- W4378216097 hasRelatedWork W3194091392 @default.
- W4378216097 hasRelatedWork W3198106554 @default.
- W4378216097 hasRelatedWork W4378216097 @default.
- W4378216097 hasVolume "14" @default.
- W4378216097 isParatext "false" @default.
- W4378216097 isRetracted "false" @default.
- W4378216097 workType "article" @default.